Dr. David Kopecky supports our life sciences patent prosecution and litigation practices in the areas of chemistry and biotechnology. Dr. Kopecky has extensive research experience in organic chemistry and medicinal chemistry.
Dr. Kopecky received his PhD in Organic Chemistry in 2001 from the University of California, Irvine. As a graduate student, he completed a formal total synthesis of leucascandrolide A, a marine macrolide with anticancer and antifungal activities. Dr. Kopecky also developed the Mukaiyama Aldol-Prins cyclization cascade reaction, and examined asymmetric alkylation reactions of pseudoephedrine amides.
Before joining the firm, Dr. Kopecky worked as a medicinal chemist at Amgen from 2001 to 2017 where he contributed to six major small molecule drug discovery programs spanning a variety of disease indications including oncology, cardiovascular diseases, and metabolic disorders. Dr. Kopecky's work at Amgen focused upon the rational design of drug candidate molecules by evaluating structure activity relationships and pharmacokinetics and drug metabolism properties.
Dr. Kopecky has been an author on sixteen organic chemistry and medicinal chemistry publications, and has been an inventor on twenty-seven Amgen small molecule patents.
- Ph.D., Chemistry, University of California, Irvine, 2001
- M.S., Chemistry, California Institute of Technology, 1998
- B.Sc., Chemistry, Brown University, 1994
- *Not admitted to the practice of law
- U.S. Patent and Trademark Office